No quarterly revenue total was found in Faeth Therapeutics, Inc.'s SEC filings.
Faeth Therapeutics, Inc. (FTH) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$13.0 million. As of Sep 30, 2026 it held $174.8 million in cash and investments and $145,000 in total debt.
Revenue
—
Net income
$-20.40M
-346.4% vs year-ago quarter
Operating cash flow
$-13.00M
-262.6% vs year-ago quarter
Free cash flow
$-13.01M
-262.7% vs year-ago quarter
EPS
$-0.79
+78.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
25.84M
+1949.0% vs year-ago quarter
Net cash
$174.65M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829802
- Former names
- Sensei Biotherapeutics, Inc. (until Jun 16, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$22.1M | -$18.4M | -$170.6M | -$5.0M | -$4.9M |
| Net income | -$20.4M | -$16.0M | -$170.2M | -$4.7M | -$4.6M |
| Diluted EPS | -$0.79 | -$2.84 | -$131.45 | -$3.74 | -$3.62 |
| Operating cash flow | -$13.0M | -$15.7M | -$10.7M | -$3.9M | -$3.6M |
| Free cash flow | -$13.0M | -$15.7M | -$10.7M | -$3.9M | -$3.6M |
| Total assets | $178.9M | $189.3M | $205.4M | $22.9M | $27.6M |
| Total liabilities | $11.1M | $9.6M | $14.2M | $4.3M | $4.6M |
| Stockholders' equity | $161.1M | $173.0M | -$137.3M | $18.6M | $23.0M |
| Cash and investments | $174.8M | $186.4M | $202.8M | $21.2M | $25.0M |
| Total debt | $145,000 | $592,000 | $1.0M | $1.5M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 17, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 452 Faeth Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.